Lewis Karen's most recent trade in Apellis Pharmaceuticals Inc was a trade of 364 Common Stock done at an average price of $29.5 . Disclosure was reported to the exchange on Jan. 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 364 | 70,251 (0%) | 0% | 29.5 | 10,747 | Common Stock |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 1,751 | 70,615 (0%) | 0% | 30.4 | 53,275 | Common Stock |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 28,508 | 72,366 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 1,241 | 43,858 (0%) | 0% | 30.0 | 37,178 | Common Stock |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 1,599 | 45,099 (0%) | 0% | 28.7 | 45,895 | Common Stock |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 29 Jan 2024 | 883 | 46,387 (0%) | 0% | 65.5 | 57,863 | Common Stock | |
| Apellis Pharmaceuticals Inc | Lewis Karen | Chief People Officer | 29 Jan 2024 | 367 | 47,270 (0%) | 0% | 64.1 | 23,539 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 23 Jan 2024 | 4,286 | 47,637 (0%) | 0% | 63.7 | 272,975 | Common Stock | |
| Apellis Pharmaceuticals Inc | Lewis Karen | Chief People Officer | 22 Jan 2024 | 1,738 | 51,923 (0%) | 0% | 65.0 | 112,963 | Common Stock | |
| Apellis Pharmaceuticals Inc | Lewis Karen | Chief People Officer | 17 Jan 2024 | 3,276 | 53,661 (0%) | 0% | 65.6 | 214,840 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 16 Jan 2024 | 24,666 | 24,666 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Lewis Karen | Chief People Officer | 16 Jan 2024 | 16,963 | 58,569 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 16 Jan 2024 | 1,632 | 56,937 (0%) | 0% | 66.8 | 109,032 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 01 Jun 2023 | 5,000 | 41,504 (0%) | 0% | 86 | 430,000 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 01 Jun 2023 | 5,000 | 106,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 01 Jun 2023 | 5,000 | 46,504 (0%) | 0% | 34.1 | 170,550 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 03 Apr 2023 | 5,000 | 41,430 (0%) | 0% | 75 | 375,000 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 03 Apr 2023 | 5,000 | 111,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 03 Apr 2023 | 5,000 | 46,430 (0%) | 0% | 34.1 | 170,550 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 23 Feb 2023 | 1,104 | 41,430 (0%) | 0% | 68.8 | 75,911 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 21 Feb 2023 | 9,402 | 9,402 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 21 Feb 2023 | 6,628 | 43,087 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 21 Feb 2023 | 553 | 42,534 (0%) | 0% | 58.5 | 32,351 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 30 Jan 2023 | 883 | 36,459 (0%) | 0% | 52.8 | 46,587 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 27 Jan 2023 | 367 | 37,342 (0%) | 0% | 52.8 | 19,367 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 23 Jan 2023 | 2,955 | 37,709 (0%) | 0% | 51.6 | 152,419 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 20 Jan 2023 | 1,411 | 40,664 (0%) | 0% | 52.1 | 73,443 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 25 Apr 2022 | 30,845 | 30,845 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 25 Apr 2022 | 19,634 | 42,075 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 25 Apr 2022 | 7,500 | 0 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 25 Apr 2022 | 1,250 | 22,224 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 28 Jan 2022 | 434 | 23,474 (0%) | 0% | 38.6 | 16,748 | Common Stock | |
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 21 Jan 2022 | 24,774 | 24,774 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 21 Jan 2022 | 17,466 | 23,908 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 28 Jan 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 28 Jan 2021 | 7,500 | 7,500 | - | - | Stock Option (Right to Buy) | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 28 Jan 2021 | 5,000 | 5,000 (0%) | 0% | 0 | Common Stock | ||
| Apellis Pharmaceuticals Inc | Karen Lewis | Chief People Officer | 28 Jan 2021 | 1,250 | 6,250 (0%) | 0% | 0 | Common Stock |